Basket cover image
8 handpicked stocks

Top Biotech Stocks

Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.

stock
stock
stock
stock
stock
stock
stock
stock
Author avatar

Han Tan | Market Analyst

Updated 1 day ago | Published at May 29

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

AMGN

Amgen Inc.

AMGN

Current price

$296.47

GILD

Gilead Sciences Inc.

GILD

Current price

$118.37

BIIB

Biogen Inc.

BIIB

Current price

$138.60

About This Group of Stocks

1

Our Expert Thinking

These biotech companies are pioneering revolutionary treatments using advanced technologies like CRISPR gene editing. With favorable regulatory environments expediting approvals and growing global demand for innovative healthcare solutions, this sector offers both meaningful impact and promising financial growth opportunities.

2

What You Need to Know

Biotech investments can offer substantial returns but typically involve longer development cycles. The industry is projected to grow from $1.55 trillion in 2023 to approximately $3.88 trillion by 2030, with regulatory support accelerating the approval of promising treatments.

3

Why These Stocks

We've selected established biotech leaders and innovative disruptors working on groundbreaking medical advancements. These companies are well-positioned to respond to increasing healthcare demands as global populations age, making them potentially valuable additions to a forward-looking investment portfolio.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+74.10%

Group Performance Snapshot

74.1%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 74.1% over the next year.

4 of 8

Stocks Rated Buy by Analysts

4 of 8 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🧬

Medical Game-Changers

These companies are developing treatments that could transform healthcare as we know it. From gene editing to novel therapies, they're tackling our biggest health challenges.

🚀

Explosive Growth Potential

The biotech industry is projected to grow at nearly 14% annually through 2030. Getting in now means positioning yourself at the start of what could be a remarkable expansion.

🔬

More Than Just Profits

By investing in biotech, you're not just seeking returns but also supporting companies developing treatments that could save millions of lives and improve countless others.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Uncle Sam's Semiconductor Stake

Uncle Sam's Semiconductor Stake

The U.S. government is considering an equity stake in Intel to boost domestic semiconductor manufacturing. This strategic move could create a ripple effect, benefiting other American companies involved in the chip-making industry.

View stocks
The Cybersecurity Consolidation Wave

The Cybersecurity Consolidation Wave

Accenture's record-breaking acquisition of CyberCX signals a major consolidation trend in the cybersecurity sector. This move highlights the growing demand for AI-powered security solutions, creating potential opportunities for other specialized cybersecurity firms to benefit from increased investment and M&A activity.

View stocks
American Chipmakers: A Tariff-Driven Shift

American Chipmakers: A Tariff-Driven Shift

President Trump has threatened to impose tariffs of up to 300% on semiconductors to boost domestic production. This creates a potential investment opportunity in U.S.-based semiconductor companies that stand to gain from a shift toward onshore manufacturing.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.